Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2017 Mar 24

PMID 28332364

Authors

Jun Pei

Tianqing Chu

Minhua Shao

Jiajun Teng

Huifang Sha

Aiqing Gu

Rong Li

Jialin Qian

Weifeng Mao

Ying Li

Baohui Han

Affiliations

Soon will be listed here.

Abstract

Purpose: c-Met and its ligand, hepatocyte growth factor (HGF), play a critical role in oncogenesis and metastatic progression. The aim of this study was to identify inhibited enzymogram and to test the antitumor activity of SIM-89 (a c-Met receptor tyrosine kinase inhibitor) in non-small cell lung cancer.

Materials And Methods: Z'-LYTE kinase assay was employed to screen the kinase enzymogram, and mechanism of action (MOA) analysis was used to identify the inhibited kinases. Cell proliferation was then analyzed by CCK8 assay, and cell migration was determined by transwell assay. The gene expression and the phosphorylation of c-Met were examined by realtime-PCR and western blotting, respectively. Finally, the secretion of HGF was detected by ELISA assay.

Results: c-Met, activated protein kinase (AMPK), and tyrosine kinase A (TRKA) were inhibited by SIM-89 with the IC₅₀ values of 297 nmol/L, 1.31 μmol/L, and 150.2 nmol/L, respectively. SIM-89 exerted adenosine triphosphate (ATP) competitive inhibition on c-Met. Moreover, the expressions of STAT1, JAK1, and c-Met in H460 cells were decreased by SIM-89 treatment, and c-Met phosphorylation was suppressed in A549, H441, H1299, and B16F10 cells by the treatment. In addition, SIM-89 treatment significantly decreased the level of HGF, which accounted for the activation of c-Met receptor tyrosine kinase. Finally, we showed cell proliferation inhibition and cell migration suppression in H460 and H1299 cells after SIM-89 treatment.

Conclusion: In conclusion, SIM-89 inhibits tumor cell proliferation, migration and HGF autocrine, suggesting it's potential antitumor activity.

References

Mao W, Shao M, Gao P, Ma J, Li H, Li G . The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacol Sin. 2012; 33(10):1311-8. PMC: 4002706. DOI: 10.1038/aps.2012.76. View

Sattler M, Reddy M, Hasina R, Gangadhar T, Salgia R . The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol. 2011; 3(4):171-84. PMC: 3150066. DOI: 10.1177/1758834011408636. View

Go H, Jeon Y, Park H, Sung S, Seo J, Chung D . High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010; 5(3):305-13. DOI: 10.1097/JTO.0b013e3181ce3d1d. View

Comoglio P, Giordano S, Trusolino L . Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; 7(6):504-16. DOI: 10.1038/nrd2530. View

Seiwert T, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M . The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009; 69(7):3021-31. PMC: 2871252. DOI: 10.1158/0008-5472.CAN-08-2881. View

Stabile L, Lyker J, Land S, Dacic S, Zamboni B, Siegfried J . Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis. 2006; 27(8):1547-55. DOI: 10.1093/carcin/bgl003. View

McDermott U, Sharma S, Dowell L, Greninger P, Montagut C, Lamb J . Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007; 104(50):19936-41. PMC: 2148401. DOI: 10.1073/pnas.0707498104. View

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

Gherardi E, Stoker M . Hepatocytes and scatter factor. Nature. 1990; 346(6281):228. DOI: 10.1038/346228b0. View

10.

Tretiakova M, Salama A, Karrison T, Ferguson M, Husain A, Vokes E . MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54. DOI: 10.1615/jenvironpatholtoxicoloncol.v30.i4.70. View

11.

Xin X, Yang S, Ingle G, Zlot C, RANGELL L, Kowalski J . Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001; 158(3):1111-20. PMC: 1850376. DOI: 10.1016/S0002-9440(10)64058-8. View

12.

Cipriani N, Abidoye O, Vokes E, Salgia R . MET as a target for treatment of chest tumors. Lung Cancer. 2008; 63(2):169-79. PMC: 2659375. DOI: 10.1016/j.lungcan.2008.06.011. View

13.

Christensen J, Burrows J, Salgia R . c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005; 225(1):1-26. DOI: 10.1016/j.canlet.2004.09.044. View

14.

Chen J, Lin T, Chow K, Huang H, Chiou S, Chiang S . Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol. 2005; 34(3):264-73. DOI: 10.1165/rcmb.2005-0117OC. View

15.

Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y . Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2008; 99(11):2280-5. PMC: 11159911. DOI: 10.1111/j.1349-7006.2008.00916.x. View

16.

Boccaccio C, Comoglio P . Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006; 6(8):637-45. DOI: 10.1038/nrc1912. View

17.

Ma P, Jagadeeswaran R, Jagadeesh S, Tretiakova M, Nallasura V, Fox E . Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005; 65(4):1479-88. DOI: 10.1158/0008-5472.CAN-04-2650. View

18.

Ravichandran K, Tyagi A, Deep G, Agarwal C, Agarwal R . Interleukin-1beta-induced iNOS expression in human lung carcinoma A549 cells: involvement of STAT and MAPK pathways. Indian J Exp Biol. 2011; 49(11):840-7. View

19.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L . Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009; 27(10):1667-74. PMC: 3341799. DOI: 10.1200/JCO.2008.19.1635. View

20.

Xiao G, Jeffers M, Bellacosa A, Mitsuuchi Y, Woude G, Testa J . Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A. 2001; 98(1):247-52. PMC: 14576. DOI: 10.1073/pnas.98.1.247. View